Kad­mon sticks a $100M toe in chilly mar­ket wa­ters

Are we see­ing a re­an­i­ma­tion of the biotech IPO mar­ket? The in­vest­ment com­mu­ni­ty cer­tain­ly hopes so, and now Kad­mon will help put it to a test.

The biotech, a brain­child of ex-CEO and founder Sam Wak­sal, has laid out terms for its IPO, look­ing to sell 5.5 mil­lion shares with­in a range of $16 to $20 per. It’s an­oth­er in­sid­er-heavy deal, with in­vestors com­mit­ting to buy up to 40% of the shares to help make it a suc­cess. And the com­pa­ny hopes to raise around $100 mil­lion in the ef­fort.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER